NewsRoom Articles - Page 6 of 1455

FridayAug 21, 2026 9:00 am

VERAXA Biotech AG (NASDAQ: VRXA) Builds Antibody-Based Cancer Pipeline Around Dual-Targeting Precision

VERAXA Biotech is changing how antibody-based therapies recognize and attack cancer cells, developing antibody-based cancer therapies with an emphasis on bispecific antibody-drug conjugates (“ADCs”) and T-cell engagers (“TCEs”). Its proprietary BiTAC platform uses a dual-targeting, “AND-gated” architecture designed to activate therapeutic effects preferentially at tumor sites. The company has advanced its lead BiTAC-TCE toward IND/CTA-enabling activities following cell-line development work and regulatory feedback from Germany’s Paul-Ehrlich-Institute. VERAXA’s VXA-222 bispecific ADC has moved beyond the initial discovery phase following completion of the antibody-discovery step with OmniAb. The company reported more than 50 granted owned or exclusively licensed patents across 26 patent…

ThursdayAug 20, 2026 9:45 am

American Fusion(TM) Inc. (AMFN) Adds Both Commercialization and International Finance Expertise as Texatron(TM) Development Continues

American Fusion, developing commercially viable small scale fusion technology, has appointed John Gerdin as an independent director and strategic advisor, adding nearly three decades of international finance and capital-markets experience, and Niclas von Schantz as a strategic advisor focused on brand strategy, commercialization, go-to-market planning, and international market development. The appointments come as American Fusion advances engineering and testing of its Texatron(TM) Fusion Engine(TM) platform. Gerdin’s experience includes corporate finance, capital formation, strategic partnerships, and international investor engagement. Von Schantz brings more than 25 years of commercialization experience spanning more than 100 brands and 50 markets, including work with Caterpillar,…

ThursdayAug 20, 2026 9:00 am

Market Street Capital Inc. Closing Financing Gap Behind US Manufacturing Reshoring

Many mid-market manufacturers cannot access the capital needed to build, retool or expand their facilities. A few factors tend to separate reshoring projects that get financed from those that stall. Market Street Capital is built to help manufacturers solve the multi-instrument structuring problem. U.S. manufacturing is in the middle of a reshoring wave. Companies are moving production back to the United States, driven by supply chain resilience needs, CHIPS Act-adjacent demand and a broader push to reduce reliance on China. According to the Reshoring Initiative’s 2024 Annual Report, more than 2 million manufacturing jobs have been announced in the United…

WednesdayAug 19, 2026 10:30 am

Earth Science Tech Inc. (ETST) Continues Steady Growth with Acquisition of California-Based Compounding Pharmacy

Earth Science Tech, an expanding health-based holding company, recently announced the acquisition of Meduvo LLC, a compounding pharmacy that currently operates from a 2,000-square-foot facility in La Verne, California The acquisition grows the company’s network to 34 jurisdictions in the United States and establishes a strategic West Coast operational hub In addition to Meduvo, ETST also operates other compounding pharmacies through its specialized subsidiaries RxCompoundStore.com LLC (“RxCS”) and Mister Meds LLC Earth Science Tech (OTC: ETST), a strategic holding company in the healthcare, pharmacy, and telemedicine sector, recently acquired Meduvo LLC, a compounding pharmacy. Meduvo currently operates from a 2,000-square-foot…

WednesdayAug 19, 2026 9:45 am

American Fusion(TM) Inc. (AMFN) Appoints Strategic Advisor as the Company Expands Scientific and IP Platform

American Fusion has added Texas Tech physicist Dr. Noah D’Amico as a Strategic Advisor. D’Amico’s work includes nuclear diagnostics, neutron detection, radiation measurement, vacuum systems and AI-assisted particle-track analysis. The company has also filed six additional U.S. patent applications, bringing its total U.S. applications to 82. American Fusion(TM) has begun testing its Texatron(TM) platform at Texas Tech University after completing initial laboratory preparations and verifying its remote ignition system. The next testing phase is expected to examine subsystems including plasma and magnetic-field control, ignition, fuel delivery and electronic components. American Fusion(TM) (OTC: AMFN), a developer of next-generation fusion energy technologies,…

WednesdayAug 19, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Myelin-Protecting MS Therapy as Treatment Paradigm Evolves

MS drug development is increasingly expanding beyond controlling inflammation toward approaches designed to protect the nervous system and address mechanisms underlying progressive disability. Remyelination and protection of existing myelin remain major unmet needs in MS, as no approved therapy has established the ability to restore previously damaged myelin. Quantum BioPharma’s Lucid-MS is a patented new chemical entity designed to inhibit demyelination and protect myelin without suppressing the immune system. The U.S. FDA has cleared Quantum BioPharma to proceed with its planned phase 2 clinical trial of Lucid-MS in people with multiple sclerosis. Multiple sclerosis (“MS”) treatment has traditionally focused on…

TuesdayAug 18, 2026 9:45 am

Market Street Capital Inc. Leverages Expertise to Close the Financing Gap for First-of-a-Kind Energy Deals

Attracting early-stage private financing can be difficult for FOAK technologies because they require large infrastructure investments without a track record, creating a “bankability gap.” A few factors tend to separate FOAK deals that get financed from ones that stall. This is the kind of multilayer structuring problem Market Street Capital is built to help sponsors navigate, not as an energy-specific lender but as an independent advisor and structurer. Every energy technology that eventually becomes “bankable” has to survive an awkward middle stage first, the point where the tech has been proven in a lab or pilot but hasn't yet run…

TuesdayAug 18, 2026 9:00 am

SS Innovations International Inc. (NASDAQ: SSII) Record Q2 Revenue Signals Continued Momentum for SSi Mantra Robotic Surgery Platform

SS Innovations, developer of innovative surgical robotic technologies, reported record second-quarter revenue of $13.9 million, up 39.4% year over year. First-half revenue reached $25.0 million, a 65.6% increase from the same period in 2025. The company’s SSi Mantra installations rose 30.4% to 30 systems during the quarter. The installed base reached 224 SSi Mantra systems across 12 countries, with 12,272 cumulative surgeries performed. U.S. and European regulatory milestones could become important catalysts, with the company targeting FDA clearance by the first quarter of 2027 and EU CE marking by the end of 2026. The company’s telesurgery achievements are extending the…

FridayAug 14, 2026 10:30 am

Earth Science Tech Inc. (ETST) Seeks to Implement a Unified Strategy to Unlock True Market Value and Support Shareholders

Earth Science Tech seeks to implement a unified strategy aimed at maximizing shareholder value, resolving structural hurdles, and elevating corporate governance The company will hold a virtual annual meeting on August 31, 2026, during which shareholders will vote on key initiatives that will position ETST for an uplisting to a higher-tier exchange, eliminate the structural barriers that hinder the infusion of institutional capital, and prevent stock dilution These initiatives are informed by extensive dialogue between shareholders and management leading to a consensus that the company’s current market valuation simply does not accurately reflect its financial success or future potential The…

FridayAug 14, 2026 9:45 am

Regentis Biomaterials Ltd. (NYSE American: RGNT) Moves GelrinC Along Parallel US Clinical and European Commercial Tracks

Regentis has passed 50% enrollment in the pivotal Phase III SAGE study of GelrinC, with recruitment completion targeted for the third quarter of 2026 and a PMA process expected to begin by the end of 2027. FDA approved a single-arm protocol using a historical microfracture control data package the company owns, and Regentis reports that the first 40 patients closely match that control group. In Europe, where GelrinC already holds CE Mark approval, surgeon training began in the third quarter of 2026 at Humanitas Research Hospital in Milan, supported by an expanded clinical site network and a newly approved manufacturing…

Financial news and publishing for public and private companies

Contact us: 512.354.7000